181 related articles for article (PubMed ID: 37531029)
1. Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008-2018: The Nationwide LANDSCAPE Study.
Creuzot Garcher CP; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Ophthalmol Ther; 2023 Oct; 12(5):2687-2701. PubMed ID: 37531029
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study.
Creuzot-Garcher CP; Srour M; Baudin F; Daien V; Dot C; Nghiem-Buffet S; Girmens JF; Coulombel N; Ponthieux A; Delcourt C
Ophthalmol Sci; 2022 Mar; 2(1):100114. PubMed ID: 36246186
[TBL] [Abstract][Full Text] [Related]
3. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
5. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
8. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
[TBL] [Abstract][Full Text] [Related]
10. Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study.
Creuzot Garcher CP; Massin P; Srour M; Baudin F; Dot C; Nghiem-Buffet S; Girmens JF; Collin C; Ponthieux A; Delcourt C
Acta Ophthalmol; 2024 Jun; 102(4):e548-e556. PubMed ID: 37874253
[TBL] [Abstract][Full Text] [Related]
11. Real world evidence of use of anti-VEGF therapy in Denmark.
Vorum H; Olesen TK; Zinck J; Størling Hedegaard M
Curr Med Res Opin; 2016 Dec; 32(12):1943-1950. PubMed ID: 27494692
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
[TBL] [Abstract][Full Text] [Related]
13. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
15. The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study.
Talks SJ; Daien V; Mitchell P; Aslam T; Barratt J; Biberger A; Lamoureux EL; Hirst C; Sylvanowicz M; Finger RP
Ophthalmol Ther; 2023 Feb; 12(1):561-575. PubMed ID: 36525220
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study).
Thoongsuwan S; Hanutsaha P; Chantarasorn Y; Ruamviboonsuk P; Vongkulsiri S; Kungwanpongpun P
Ophthalmol Ther; 2022 Apr; 11(2):739-757. PubMed ID: 35149964
[TBL] [Abstract][Full Text] [Related]
18. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
[TBL] [Abstract][Full Text] [Related]
19. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
[TBL] [Abstract][Full Text] [Related]
20. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
